Microvascular Therapeutics
Membership Level: Standard Community
Microvascular Therapeutics (MVT) has developed a new, patented formulation, MVT-100, for use as an ultrasound contrast agent. MVT-100 has a neutral surface chemistry, potentially serving as a platform for the development of agents for molecular imaging and image-guided therapy. MVT received formal guidance from the FDA that MVT-100 can be developed via the 505(b)(2) pathway. The Company has designed an accelerated development pathway to potentially lead to the approval of MVT-100 for echocardiography.
More